Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POLR2A siRNA
- Development stage
- Preclinical
- Lead developer
- Indiana University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
POLR2A siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the POLR2A gene, which encodes RNA polymerase II subunit A (RPB1), the largest subunit of the RNA polymerase II complex. In preclinical research, POLR2A siRNA has been investigated for its therapeutic potential in acute kidney injury (AKI) and chronic kidney disease (CKD) by preventing proximal tubule cells from being trapped in a dedifferentiated state. Additionally, POLR2A siRNA has been studied as a targeted therapy for cancers harboring hemizygous loss of TP53 and POLR2A (such as triple-negative breast cancer and colorectal cancer), exploiting a collateral vulnerability where partial loss of POLR2A renders cancer cells highly sensitive to further POLR2A suppression.
- Other names
- POLR2A small interfering RNAPOLR-2A small interfering RNAPOLR 2A small interfering RNAsiPol2siPol-2siPol 2siPolr2siPolr-2siPolr 2
02
Targets
Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on POLR2A siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLR2A siRNA.